Company Filing History:
2 out of 3,539 
2 out of 2,489 
Years Active: 2022-2024
Title: Mark Louder: Innovator in HIV-1 Research
Introduction
Mark Louder is a notable inventor based in Mt. Airy, MD (US), recognized for his contributions to the field of HIV-1 research. He holds two patents that focus on neutralizing antibodies aimed at combating HIV-1 infections. His work has significant implications for the development of treatments and detection methods for this virus.
Latest Patents
Louder's latest patents include "10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use." This patent discloses neutralizing antibodies that specifically bind to HIV-1 Env, along with antigen binding fragments of these antibodies. It also provides nucleic acids encoding these antibodies, vectors, and host cells. Furthermore, methods for detecting HIV-1 using these antibodies are outlined. The patent emphasizes the use of these antibodies, antigen binding fragments, nucleic acids, and vectors to prevent and/or treat HIV-1 infections. Another patent, "Neutralizing antibodies to HIV-1 GP41 and their use," shares similar disclosures and applications, reinforcing Louder's commitment to advancing HIV-1 research.
Career Highlights
Throughout his career, Louder has worked with esteemed organizations, including the Government of the United States of America as represented by the Secretary of the Department of Health and Human Services and Columbia University. His work in these institutions has allowed him to contribute significantly to public health and scientific research.
Collaborations
Louder has collaborated with notable colleagues such as Young Do Kwon and Ivelin Georgiev. These partnerships have enhanced his research efforts and broadened the impact of his innovations in the field.
Conclusion
Mark Louder's innovative work in developing neutralizing antibodies for HIV-1 showcases his dedication to addressing critical health challenges. His patents and collaborations reflect a commitment to advancing medical science and improving treatment options for those affected by HIV-1.